Bayesian Capital Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
Other funds holding MYGN
Bayesian Capital Management's MYGN Position: Q3 2026 in Review
Bayesian Capital Management opened a new position in Myriad Genetics (MYGN) in Q3 2026: 19,800 shares worth $85.3K. The stake represents 0.07% of the portfolio and ranks #164 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in MYGN as recently as Q3 2025.
Bayesian Capital Management first reported a position in MYGN in Q1 2017 and has held it in 6 quarters since. The position peaked at $783K in Q4 2017. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.
- Bayesian Capital Management held 19,800 shares of Myriad Genetics worth $85.3K as of Q3 2026.
- Myriad Genetics was a new Bayesian Capital Management position in Q3 2026.
- Myriad Genetics made up 0.07% of Bayesian Capital Management's portfolio in Q3 2026, its #164 holding.
- Bayesian Capital Management first reported a position in Myriad Genetics in Q1 2017 and has held it in 6 quarters since.
- Bayesian Capital Management's Myriad Genetics position peaked at $783K in Q4 2017.
- 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.
Based on Bayesian Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.